Adam S. Lauring
A5047332848- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- Respiratory viral infections research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 detection and testing
- COVID-19 epidemiological studies
- Evolution and Genetic Dynamics
- RNA and protein synthesis mechanisms
- Plant Virus Research Studies
- Animal Virus Infections Studies
- HIV Research and Treatment
- Viral Infections and Outbreaks Research
- Viral Infections and Immunology Research
- CRISPR and Genetic Engineering
- Pneumonia and Respiratory Infections
- Animal Disease Management and Epidemiology
- Respiratory Support and Mechanisms
- Virus-based gene therapy research
- Hepatitis B Virus Studies
- Infection Control and Ventilation
- Long-Term Effects of COVID-19
- COVID-19 Impact on Reproduction
- interferon and immune responses
University of Michigan
2016-2025
Michigan United
2014-2025
Barnes-Jewish Hospital
2021-2024
Baystate Medical Center
2021-2024
University of Colorado Denver
2021-2024
Hennepin County Medical Center
2021-2024
Vanderbilt University Medical Center
2020-2024
University of Pittsburgh
2020-2024
Atrium Health Wake Forest Baptist
2021-2024
Intermountain Medical Center
2021-2024
Background. Encephalitis continues to result in substantial morbidity and mortality worldwide. Advances diagnosis management have been limited, part, by a lack of consensus on case definitions, standardized diagnostic approaches, priorities for research.
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly due to altered antibody evasion properties deriving from their additional spike mutations. Here, we report that neutralization BQ.1, BQ.1.1, XBB, XBB.1 by sera vaccinees infected persons was markedly impaired, including individuals boosted with a WA1/BA.5 bivalent mRNA vaccine. Titers against were lower 13- 81-fold 66- 155-fold, respectively, far beyond what had been observed date. Monoclonal antibodies...
This Viewpoint discusses emerging genetic variants of SARS-CoV-2, including new "UK" and "mink" the significance to coronavirus transmissibility, spread, virulence, efforts vaccinate population against COVID-19.
A comprehensive understanding of the benefits COVID-19 vaccination requires consideration disease attenuation, determined as whether people who develop despite have lower severity than unvaccinated people.
To characterize the clinical severity of covid-19 associated with alpha, delta, and omicron SARS-CoV-2 variants among adults admitted to hospital compare effectiveness mRNA vaccines prevent admissions related each variant.
Abstract Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid decompensation and respiratory failure with elevated inflammatory markers, consistent cytokine release syndrome for which IL-6 blockade is an approved treatment. Methods We assessed effectiveness safety of tocilizumab a single-center cohort patients COVID-19 requiring mechanical ventilation. The primary endpoint was survival probability postintubation; secondary analyses included ordinal illness severity...
Data are not complete for all characteristics in the table; denominators
Abstract We describe a case of chronic coronavirus disease 2019 (COVID-19) in patient with lymphoma and associated B-cell immunodeficiency. Viral cultures sequence analysis demonstrate ongoing replication infectious severe acute respiratory syndrome 2 (SARS-CoV-2) for at least 119 days. The had 3 admissions related to COVID-19 over 4-month period was treated twice remdesivir convalescent plasma resolution symptoms. patient’s lack seroconversion prolonged course illustrate the importance...
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first vaccines approved use under an Emergency Use Authorization (EUA) in United States (1-3). In evaluation 24 hospitals 14 states,* effectiveness of partial or full vaccination† with Pfizer-BioNTech Moderna against COVID-19-associated hospitalization was assessed among adults years. Among 417 hospitalized (including 187 case-patients 230 controls), median age...
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability protection. In an evaluation at 21 hospitals in 18 states, the duration mRNA vaccine (Pfizer-BioNTech or Moderna) (VE) was assessed among adults aged ≥18 years. Among 3,089 hospitalized (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), median age 59 years,...
The evolutionary dynamics of influenza virus ultimately derive from processes that take place within and between infected individuals. Here we define in human hosts through sequencing 249 specimens 200 individuals collected over 6290 person-seasons observation. Because these viruses were a prospective community-based cohort, they are broadly representative natural infections with seasonal viruses. Consistent neutral model evolution, sequence data 49 serially sampled illustrated the dynamic...
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are effective at preventing COVID-19-associated hospitalization (1-3). However, how well protect against the most severe outcomes of these hospitalizations, including invasive mechanical ventilation (IMV) or death is uncertain. Using a case-control design, vaccine effectiveness (VE) IMV in-hospital was evaluated among adults aged ≥18 years hospitalized 21 U.S. medical centers during March 11, 2021-January 24, 2022....
Traditional influenza surveillance informs control strategies but can lag behind outbreak onset and undercount cases. Wastewater is effective for monitoring near real-time dynamics of outbreaks has not been attempted influenza. We quantified A virus (IAV) RNA in wastewater during two active on university campuses different parts the United States times year using case data from an investigation high-quality student athletes. In both cases, IAV concentrations were strongly associated with...
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage increases in the United States, there is a need to understand real-world effectiveness against disease 2019 (COVID-19) and among people at increased risk for poor outcomes.In multicenter case-control analysis of US adults hospitalized March 11-May 5, 2021, we evaluated vaccine prevent COVID-19 hospitalizations by comparing odds prior with messenger RNA (mRNA) (Pfizer-BioNTech or Moderna) between cases...
We describe a case of proven transmission SARS-CoV-2 from lung donor to recipient. The had no clinical history or findings suggestive infection with and tested negative by reverse transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal (NP) swab obtained within 48 h procurement. Lower respiratory tract testing was not performed. recipient developed fever, hypotension, pulmonary infiltrates posttransplant day (PTD) 3, RT-PCR for an NP specimen non-reactive, but positive...
Analysis of SARS-CoV-2 genetic diversity within infected hosts can provide insight into the generation and spread new viral variants may enable high resolution inference transmission chains. However, little is known about temporal aspects intrahost extent to which shared reflects convergent evolution as opposed linkage. Here we use depth coverage sequencing identify within-host in 325 specimens from hospitalized COVID-19 patients employees at a single medical center. We validated our variant...
Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully reduced COVID-19-related morbidity and mortality in United States globally (1,2). However, vaccine effectiveness (VE) COVID-19-associated hospitalization has declined over time, likely related to a combination factors, including waning immunity and, with emergence Omicron variant its sublineages, immune evasion (3). To address these on September 1, 2022, Advisory Committee Immunization...
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection against infection with SARS-CoV-2, the virus that causes COVID-19, are highly effective COVID-19-associated hospitalization among eligible persons who receive 2 doses (1,2). However, vaccine effectiveness (VE) immunocompromising conditions* is lower than immunocompetent (2), VE declines after several months all (3). On August 12, 2021, Food Drug Administration (FDA) issued an emergency use...
Abstract Objective To compare the effectiveness of a primary covid-19 vaccine series plus booster doses with alone for prevention hospital admission omicron related in United States. Design Multicenter observational case-control study test negative design. Setting Hospitals 18 US states. Participants 4760 adults admitted to one 21 hospitals acute respiratory symptoms between 26 December 2021 and 30 June 2022, period when variant was dominant. included 2385 (50.1%) patients laboratory...